One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Inflammatory tissue priming: novel insights and therapeutic opportunities for inflammatory rheumatic diseases
doi : 10.1136/ard-2023-224092
2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases
doi : 10.1136/ard-2023-224514
Patient research partner involvement in rheumatology research: a systematic literature review informing the 2023 updated EULAR recommendations for the involvement of patient research partners
doi : 10.1136/ard-2024-225567
Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease
doi : 10.1136/ard-2024-225914
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
doi : 10.1136/ard-2024-225523
Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
doi : 10.1136/ard-2024-225613
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
doi : 10.1136/ard-2024-225785
Haematopoietic stem cell-derived immune cells have reduced X chromosome inactivation skewing in systemic lupus erythematosus
doi : 10.1136/ard-2024-225585
Blood RNA-sequencing across the continuum of ANA-positive autoimmunity reveals insights into initiating immunopathology
doi : 10.1136/ard-2023-225349
Single-cell transcriptomes and chromatin accessibility of endothelial cells unravel transcription factors associated with dysregulated angiogenesis in systemic sclerosis
doi : 10.1136/ard-2023-225415
CD8+ tissue-resident memory T cells are expanded in primary Sjögren's disease and can be therapeutically targeted by CD103 blockade
doi : 10.1136/ard-2023-225069
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX
doi : 10.1136/ard-2024-225640
Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout
doi : 10.1136/ard-2024-225761
Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain
doi : 10.1136/ard-2023-225414
CPPD disease presenting with acute arthritis of the first metatarsophalangeal joint
doi : 10.1136/ard-2024-225892
Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series
doi : 10.1136/ard-2024-225800
Cardiac valve immune profiling in non-radiographic axial spondyloarthritis
doi : 10.1136/ard-2024-225942
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
doi : 10.1136/ard-2024-225696
Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al
doi : 10.1136/ard-2024-225563
Response to: Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al
doi : 10.1136/ard-2024-225617
Correspondence on ‘EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update’ by Hellmich et al
doi : 10.1136/ard-2024-225583
Response to: Correspondence on ‘EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update’ by Hellmich et al
doi : 10.1136/ard-2024-225606
